Introduction: The First-Generation Ghrelin Mimetics
Growth hormone-releasing peptides (GHRPs) represent a class of synthetic compounds that stimulate growth hormone (GH) release through the ghrelin receptor (GHS-R1a). GHRP-2 and GHRP-6 are the two most widely studied compounds in this class, having served as foundational tools that led to the discovery of the ghrelin receptor and ghrelin itself. They share the same receptor target but differ in GH potency, appetite effects, cortisol stimulation, and practical applications.
This comparison examines both compounds across structural pharmacology, receptor binding, GH release profiles, off-target hormonal effects, metabolic effects, cardiovascular properties, and research applications. We contextualize them within the broader GH secretagogue landscape including ipamorelin and CJC-1295 No DAC.
Historical Context
In 1977, Cyril Bowers observed that enkephalin analogs stimulated GH release through a non-GHRH mechanism. GHRP-6 was developed in 1984 as the first potent GH-releasing hexapeptide. GHRP-2 followed in the 1990s with higher potency and reduced appetite effects. In 1996, Howard et al. identified the GHS-R1a receptor using GHRP-6 as the screening ligand. In 1999, Kojima et al. identified ghrelin as the endogenous ligand.
Structural Comparison
GHRP-6: His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, MW ~873 Da. His-1 contributes to appetite via hypothalamic histamine. D-Trp-2 provides stability and beta-turn structure.
GHRP-2: D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2, MW ~817 Da. D-Ala-1 eliminates histamine-mediated appetite. D-2-Nal-2 provides larger aromatic surface for enhanced binding, explaining higher potency.
Receptor Pharmacology
Both are full GHS-R1a agonists (Gq-PLC-IP3-calcium signaling). GHRP-2 has 2-3x higher binding affinity. Both also bind CD36 (cardioprotective) and activate corticotrophs/lactotrophs (cortisol/prolactin release).
GH Release Profiles
GHRP-2 at 100-300 mcg SC: peak GH 15-40 mcg/L (5-15x baseline). GHRP-6 at equivalent doses: peak GH 10-25 mcg/L (3-10x baseline). Both peak at 15-30 min, return to baseline in 2-3 hours. Both synergize with CJC-1295 (3-5x additive GH release). Tachyphylaxis: GHRP-6 30-50%, GHRP-2 25-40% over 2-4 weeks.
Off-Target Effects
Cortisol: Both 50-100% increase. Prolactin: Both 20-50% increase. Appetite: GHRP-6 strong (His-1 mediated); GHRP-2 moderate (D-Ala eliminates His component). This appetite difference is the most practically significant distinction.
Metabolic Effects
Both increase fasting glucose 5-10 mg/dL. GHRP-6 appetite may promote net fat gain under ad libitum feeding. Both produce CD36-mediated cardioprotection independent of GH. GHRP-6 more extensively studied cardiovascularly.
Regulatory Status
GHRP-2 (pralmorelin): approved in Japan for GH deficiency diagnosis. GHRP-6: not approved anywhere but extensively published over 4 decades.
Research Applications
Choose GHRP-2: Maximum GH potency, metabolic studies (lower appetite confounding), regulatory-grade safety data, diagnostic testing.
Choose GHRP-6: Appetite/feeding research, cachexia studies, cardiovascular research, cost-sensitive protocols.
Choose Ipamorelin: Clean GH selectivity, combination with CJC-1295 No DAC. Ipamorelin is preferred for most modern protocols.
Comparison Table
| Parameter | GHRP-2 | GHRP-6 |
|---|---|---|
| MW | ~817 Da | ~873 Da |
| GH Potency | Higher (40-60% more) | Moderate (reference) |
| Cortisol | Significant | Significant |
| Appetite | Moderate | Strong |
| CD36 Cardio | Less studied | Well-documented |
| Tachyphylaxis | 25-40% | 30-50% |
| Regulatory | Japan-approved (dx) | Not approved |
Conclusion
GHRP-2 offers higher GH potency and moderate appetite effects. GHRP-6 offers robust appetite stimulation and better-characterized cardiovascular effects. Both produce significant cortisol/prolactin stimulation. For clean GH selectivity, ipamorelin with CJC-1295 No DAC has largely supplanted both.
References
- Bowers CY, et al. Endocrinology. 1984;114(5):1537-1545.
- Howard AD, et al. Science. 1996;273:974-977.
- Kojima M, et al. Nature. 1999;402:656-660.
- Raun K, et al. Eur J Endocrinol. 1998;139:552-561.
- Berlanga-Acosta J, et al. Medicc Rev. 2012;14(2):40-44.
- Popovic V, et al. Pituitary. 2003;6(3):141-146.
- Muccioli G, et al. Ann Endocrinol. 2000;61(1):27-31.
- Sigalos JT, et al. Sex Med Rev. 2018;6(1):45-53.
For educational/research purposes only. Visit Proxiva Labs for research peptides.